CRH (CRH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Mar, 2026Executive summary
Delivered record 2025 financial results: revenues up 5% to $37.4B, net income up 8% to $3.8B, Adjusted EBITDA up 11% to $7.7B, and Diluted EPS up 10% to $5.51.
Achieved Total Shareholder Return of 36.8% for 2025, with share price rising from $92.52 to $124.80.
Invested $4.1B in 38 acquisitions, including $2.1B for Eco Material Technologies, and $1.7B in growth capex.
Continued share buybacks ($1.2B) and increased dividend by 6% to $1.48 per share.
Announced intention to delist from the LSE and cancel legacy Preference Shares, subject to shareholder approval.
Voting matters and shareholder proposals
12 proposals at the 2026 AGM: re-election of 12 directors, advisory vote on executive compensation, auditor appointment and compensation, renewal of share issuance and buyback authorities, cancellation of Preference Shares, and amendments to Articles.
Special business includes cancellation of 5% and 7% Preference Shares via court-approved schemes, with cash consideration at a significant premium to nominal value.
Proposal to amend Articles to remove director qualification shareholding requirement.
Board of directors and corporate governance
Board comprises 12 directors with diverse backgrounds and skills; all standing for re-election.
Board evaluation process includes external facilitation; annual review of director performance and independence.
Five standing committees: Audit, Compensation, Nomination & Corporate Governance, Acquisitions/Divestments & Finance, and Safety, Environment & Social Responsibility.
Chair and CEO roles are separated; robust succession planning in place.
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - Strong growth and cash generation cut leverage to 1.7x while supporting further growth.CRH
H2 2016 - €3.3bn EBITDA, stronger margins and returns, and major acquisitions positioned for further growth.CRH
H2 2017 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - H2 momentum improved as portfolio actions and disciplined investment set up a moderate 2014 recovery.CRH
H2 2013 - EBITDA rose 11% in 2014; 2015 priorities were growth, integration and debt reduction.CRH
H2 2014 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Cash discipline and cost savings steadied results as markets began to stabilize.CRH
H2 2010 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026 - Q2 2026 saw strong growth, margin gains, and the Arcosa deal, supporting a positive outlook.CRH
Q2 2026